Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children

AIDS

Volumn 25, Issue 3, 2011, Pages 315-323

  Bunupuradah, Torsak ^a   Kosalaraksa, Pope ^b   Puthanakit, Thanyawee ^a,c   Mengthaisong, Tawan ^a   Wongsabut, Jiratchaya ^a   Lumbiganon, Pagakrong ^b   Phanuphak, Praphan ^a   Burger, David ^d   Pancharoen, Chitsanu ^c   Ananworanich, Jintanat ^a,c,e  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e South East Asia Research Collaboration with Hawaii ^*  (Thailand)

Author keywords

children; HIV; lopinavir monotherapy; protease inhibitor; treatment simplification

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; THAILAND;

EID: 79551590056     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834231f5     Document Type: Article

References (20)

1. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS (London, England) 2009; 23:279-291.
2. Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez-Garcia J, Perez-Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS (London, England) 2008; 22:F1-F9.
3. Arribas JR, Delgado R, Arranz A, Munoz R, Portilla J, Pasquau J, et al. Lopinavir-ritonavirmonotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir ImmuneDefic Syndr (1999) 2009; 51:147-152.
4. Pulido F, Perez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009; 14:195-201.
5. Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, et al. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. AIDS Res Hum Retroviruses 2009; 25:269-275.
6. Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai 2008; 91:1925-1935.
7. Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, et al. Safety and efficacy of a doubleboosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther 2009; 14:241-248.
8. Sirivichayakul S, RuxrungthamK, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS (London, England) 2003; 17:1889-1896.
9. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
10. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversedphase high-performance liquid chromatography. Ther Drug Monitor 2003; 25:393-399.
11. National Institute of Allergy and Infectious Disease. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. http://www3.niaid.nih.gov/research/resour ces/DAIDSClinRsrch/PDF/Safety/ DAIDSAEGradingTable.pdf; 2004.
12. Arribas F R, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr (1999) 2005; 40:280-287.
13. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16:62-68.
14. Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, et al. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J 2008; 27:623-628.
15. Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J, Gorowara M, Phasomsap C, et al. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIVinfected children. J Antimicrob Chemother 2009; 64:1080-1086.
16. Bunupuradah T, Aurpibul L, Ananworanich J, Puthanakit T. The effectiveness of highly active antiretroviral therapy among HIV-infected children in Asian countries. Asian Biomed 2009; 3:89-100.
17. Jaspan HB, Berrisford AE, Boulle AM. Two-year outcomes of children on nonnucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J 2008; 27:993-998.
18. Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, et al. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009; 53:2934-2939.
19. Tebas P, Henry WK, Matining R, Weng-Cherng D, Schmitz J, Valdez H, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PloS One 2008; 3:e2021.
20. Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below50 copies/ml. AIDS(London, England) 2010; 24:223-230.